ClinicalTrials.gg
CompletedNCT00463437Updated Jan 2, 2020Results posted

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

A Phase 3 interventional study of Pneumococcal conjugate vaccine GSK1024850A and Prevenar in Hepatitis B, Acellular Pertussis and Tetanus, sponsored by GlaxoSmithKline. Completed at 63 sites in 3 countries. Open to participants aged 11 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,437
Allocation
Randomized
Ages
11 Months to 18 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.

Enrollment
Largest of 16
1,437 · median 417
Started
2007
with 1 other
Phase 3
7 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
14 of 16
GlaxoSmithKline

Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one has the largest enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 4th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 11 Months to 18 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B as a file.
02

Study summary

The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus influenzae type b (Hib-MenC) vaccine.

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334).

Read the detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

03

Conditions studied

  • Hepatitis B
  • Acellular Pertussis
  • Tetanus
  • Poliomyelitis
  • Diphtheria
  • Streptococcus Pneumoniae Vaccines

Keywords

  • Fever.
  • Meningococcal disease.
  • Pneumococcal disease.
  • Meningococcal vaccine.
  • Pneumococcal vaccine.
  • Immunogenicity.
  • Booster vaccination.
  • Safety.
04

Who can participate

Ages eligible
11 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 11-18 months of age at the time of the booster vaccination.
  • A male or female who previously participated in study 107005 and received three doses of pneumococcal conjugate vaccine.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Concurrently participating in another clinical study, at any time during the study period (active phase and extended safety follow-up), in which the subject has been or will be exposed to an or a non-investigational product.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within one month preceding the booster dose of study vaccines, or planned use during the entire study period
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs within 6 months prior to the booster dose of study vaccines.
  • Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting one month before the booster dose of study vaccines and up to the follow-up visit (one month after the booster dose of study vaccines).
  • Administration of any pneumococcal, diphtheria, tetanus, pertussis, polio, , Haemophilus influenzae type b, MenC and/or Hib-MenC vaccines other than the study vaccines from study 107005.
  • History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, meningococcal serogroup C disease.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or progressive neurological disease.
  • Acute disease at the time of enrolment.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious chronic illness.
  • Administration of immunoglobulins and/or any blood products within three months preceding the booster dose of study vaccines or planned administration during the active phase of the study (starting with the administration of the booster dose of study vaccines up to the follow-up visit one month after).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,437 participants (actual)

Study arms

  • Experimental
    GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™

    Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa · Biological: Infanrix IPV Hib · Biological: Meningitec

  • Experimental
    GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™

    Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa · Biological: Infanrix IPV Hib · Biological: NeisVac-C

  • Experimental
    GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™

    Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix penta · Biological: Infanrix IPV · Biological: Menitorix

  • Active comparator
    Prevenar™ + Menitorix™

    Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.

    Biological: Prevenar · Biological: Infanrix penta · Biological: Infanrix IPV · Biological: Menitorix

Interventions

  • Intramuscular injection, 1 dose.

  • BiologicalPrevenar

    Intramuscular injection, 1 dose.

    Also known as: Pneumococcal conjugate vaccine (Wyeth Lederle).

  • BiologicalInfanrix hexa

    Intramuscular injection, 1 dose. In Germany and Poland.

    Also known as: DTPa-HBV-IPV/Hib (GSK Biologicals).

  • BiologicalInfanrix IPV Hib

    Intramuscular injection, 1 dose. In Spain.

    Also known as: DTPa-IPV/Hib (GSK Biologicals).

  • BiologicalInfanrix penta

    Intramuscular injection, 1 dose. In Germany and Poland.

    Also known as: DTPa-HBV-IPV (GSK Biologicals).

  • BiologicalInfanrix IPV

    Intramuscular injection, 1 dose. In Spain.

    Also known as: DTPa-IPV (GSK Biologicals)

  • BiologicalMeningitec

    Intramuscular injection, 1 dose.

    Also known as: Meningococcal C conjugate vaccine (Wyeth).

  • BiologicalNeisVac-C

    Intramuscular injection, 1 dose.

    Also known as: Meningococcal C conjugate vaccine (Baxter).

  • BiologicalMenitorix

    Intramuscular injection, 1 dose.

    Also known as: Combined Hib-MenC vaccine (GSK Biologicals).

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)

    Fever was measured as rectal temperature.

    Time frame: During the 4-day (Day 0-3) period after the booster vaccination

Secondary outcomes

  1. Number of Subjects Reporting Solicited Local Symptoms

    Solicited local symptoms assessed include pain, redness and swelling.

    Time frame: During the 4-day (Day 0-3) period after the booster vaccination

  2. Number of Subjects Reporting Solicited General Symptoms

    Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.

    Time frame: During the 4-day (Day 0-3) period after the booster vaccination

  3. Number of Subjects Reporting Unsolicited Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: During the 31-day (Day 0-30) period after the booster vaccination

  4. Number of Subjects Reporting Serious Adverse Events (SAE)

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

    Time frame: During the 31-day (Day 0-30) period after the booster vaccination

  5. Number of Subjects Reporting Serious Adverse Events (SAE)

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

    Time frame: From the beginning of the study up to the end of the extended 6-month safety follow-up period

  6. Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

    Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: Before (pre) and one month after (post) the booster administration

  7. Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value

    Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.

    Time frame: Before (pre) and one month after (post) the booster administration

  8. Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

    Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

    Time frame: Before (pre) and one month after (post) the booster administration

  9. Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value

    Anti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

    Time frame: Before (pre) and one month after (post) the booster administration

  10. Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value

    Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).

    Time frame: Before (pre) and one month after (post) the booster administration

  11. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value

    Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.

    Time frame: Before (pre) and one month after (post) the booster administration

  12. Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value

    Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.

    Time frame: Before (pre) and one month after (post) the booster administration

  13. Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value

    Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.

    Time frame: Before (pre) and one month after (post) the booster administration

07

Results

Posted Aug 3, 2009

Participant flow

Participant flow — Overall Study
MilestoneGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Started359363358357
Completed355352352350
Not completed41167

Outcome measures

PrimaryNumber of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)

Fever was measured as rectal temperature.

Time frame:
During the 4-day (Day 0-3) period after the booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)——118
SecondaryNumber of Subjects Reporting Solicited Local Symptoms

Solicited local symptoms assessed include pain, redness and swelling.

Time frame:
During the 4-day (Day 0-3) period after the booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Solicited Local Symptoms
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Pain196195193165
Redness194183186173
Swelling162148150134
SecondaryNumber of Subjects Reporting Solicited General Symptoms

Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.

Time frame:
During the 4-day (Day 0-3) period after the booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Solicited General Symptoms
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Drowsiness124142139105
Fever (≥ 38.0 °C)109122105108
Irritability170190191157
Loss of appetite1019911293
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events (AE)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
During the 31-day (Day 0-30) period after the booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Unsolicited Adverse Events (AE)
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Number of Subjects Reporting Unsolicited Adverse Events (AE)59745976
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

Time frame:
During the 31-day (Day 0-30) period after the booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAE)
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Number of Subjects Reporting Serious Adverse Events (SAE)3532
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

Time frame:
From the beginning of the study up to the end of the extended 6-month safety follow-up period
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAE)
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Number of Subjects Reporting Serious Adverse Events (SAE)1591313
SecondaryNumber of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Anti-1 pre (n=150,152,149, 151)14614614021
Anti-1 post (n=158,152,160,151)15815216028
Anti-4 pre (n=153,156,150,153)152156147150
Anti-4 post (n=158,153,160,152)158153160152
Anti-5 pre (n=149,146,146,148)14914614437
Anti-5 post (n=157,153,160,150)15715316064
Anti-6B pre (n=151,155,150,151)149153144137
Anti-6B post (n=158,153,160,153)157151158153
Anti-7F pre (n=149,153,148,151)14915314718
Anti-7F post (n=158,152,160,151)15815216025
Anti-9V pre (n=149,155,149,152)149154149152
Anti-9V post (n=158,153,160,153)158152160153
Anti-14 pre (n=153,158,152,153)151157152151
Anti-14 post (n=158,153,160,153)158153160153
Anti-18C pre (n=151,153,145,151)149151145151
Anti-18C post (n=157,152,160,152)157152160152
Anti-19F pre (n=143,146,139,150)143146139143
Anti-19F post (n=158,151,160,152)158151160152
Anti-23F pre (n=152,156,150,153)149153144141
Anti-23F post (n=158,153,160,153)158152158153
SecondaryNumber of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value

Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Opsono-1 pre (n=144,145,141,143)4639418
Opsono-1 post (n=140,139,140,137)13213312712
Opsono-4 pre (n=104,121,112,109)61676173
Opsono-4 post (n=137,134,140,135)137134140135
Opsono-5 pre (n=116,114,117,124)7771723
Opsono-5 post (n=124,130,136,127)1211271314
Opsono-6B pre (n=133,132,133,137)75607567
Opsono-6B post (n=142,135,142,140)134127135138
Opsono-7F pre (n=111,122,115,104)10911710942
Opsono-7F post (n=140,137,139,112)14013713953
Opsono-9V pre (n=133,133,130,130)131130122126
Opsono-9V post (n=143,139,143,137)143139143137
Opsono-14 pre (n=121,125,114,125)115116107124
Opsono-14 post (n=137,138,138,134)137138138134
Opsono-18C pre (n=126,118,123,123)45543435
Opsono-18C post (n=121,129,121,114)121127121110
Opsono-19F pre (n=127,135,134,134)1021109529
Opsono-19F post (n=137,137,139,133)133132139131
Opsono-23F pre (n=132,136,128,137)121120105124
Opsono-23F post (n=145,143,146,143)145143146143
SecondaryNumber of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Anti-6A pre (n=145,144,144,149)126120119110
Anti-6A post (n=156,152,159,152)152145149148
Anti-19A pre (n=145,153,145,151)13013812187
Anti-19A post (n=157,153,160,152)154151155149
SecondaryNumber of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value

Anti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Opsono-6A pre (n=108,110,106,110)68667362
Opsono-6A post (n=127,128,128,122)116119117119
Opsono-19A pre (n=133,138,136,134)41142
Opsono-19A post (n=124,132,130,123)77755029
SecondaryNumber of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value

Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Pre (n=147,153,147,146)14414713859
Post (n=158,152,160,148)15815116066
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value

Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Pre (n=68,65,66,78)57626268
Post (n=89,84,79,76)89847976
SecondaryNumber of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value

Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Pre (n=126,124,125,135)9582105102
Post (n=156,149,159,149)156149159149
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value

Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.

Time frame:
Before (pre) and one month after (post) the booster administration
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value
subjectsGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Pre (n=147,144,150,148)122128145143
Post (n=157,153,160,152)157153160152

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™——297/359 (82.7%)
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™——303/363 (83.5%)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™——302/358 (84.4%)
Prevenar™ + Menitorix™——287/357 (80.4%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
Gastroenteritis rotavirusGastrointestinal disorders4/3590/3631/3580/357
GastroenteritisInfections and infestations2/3594/3632/3583/357
PneumoniaInfections and infestations2/3591/3630/3583/357
Febrile convulsionNervous system disorders0/3591/3632/3582/357
BronchopneumoniaInfections and infestations1/3591/3630/3582/357
DiarrhoeaGastrointestinal disorders0/3590/3630/3582/357
PharyngitisInfections and infestations0/3591/3632/3580/357
Thermal burnInjury, poisoning and procedural complications2/3590/3631/3580/357
BronchitisInfections and infestations1/3590/3631/3581/357
ConcussionInjury, poisoning and procedural complications0/3590/3630/3581/357
Most frequent other events
Most frequent other events
EventGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™
PainGeneral disorders196/359195/363193/358165/357
RednessGeneral disorders194/359183/363186/358173/357
IrritabilityGeneral disorders170/359190/363191/358157/357
SwellingGeneral disorders162/359148/363150/358134/357
DrowsinessGeneral disorders124/359142/363139/358105/357
FeverGeneral disorders109/359122/363105/358108/357
Loss of appetiteGeneral disorders101/35999/363112/35893/357
Upper respiratory tract infectionInfections and infestations6/35919/36314/35818/357

Baseline characteristics

Age, Continuous
Age, Continuous(Months)GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™Total
Mean14.3 ± 1.8114.3 ± 1.7414.3 ± 1.7814.3 ± 1.7814.3 ± 1.78
Sex: Female, Male
Sex: Female, Male(Participants)GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™Total
Female182176195171724
Male177187163186713
08

Study locations

63 sites
  • GSK Investigational Site
    Bad Saulgau, Baden-Wuerttemberg 88348, Germany
  • GSK Investigational Site
    Boennigheim, Baden-Wuerttemberg 74357, Germany
  • GSK Investigational Site
    Bretten, Baden-Wuerttemberg 75015, Germany
  • GSK Investigational Site
    Ettenheim, Baden-Wuerttemberg 77955, Germany
  • GSK Investigational Site
    Karlsruhe, Baden-Wuerttemberg 76189, Germany
  • GSK Investigational Site
    Kehl, Baden-Wuerttemberg 77694, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Oberstenfeld, Baden-Wuerttemberg 71720, Germany
  • GSK Investigational Site
    Schwaebisch-Hall, Baden-Wuerttemberg 74523, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70469, Germany
  • GSK Investigational Site
    Tettnang, Baden-Wuerttemberg 88069, Germany
  • GSK Investigational Site
    Cham, Bayern 93413, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81735, Germany
  • GSK Investigational Site
    Noerdlingen, Bayern 86720, Germany
  • GSK Investigational Site
    Olching, Bayern 82140, Germany
  • GSK Investigational Site
    Roding, Bayern 93426, Germany
  • GSK Investigational Site
    Eschwege, Hessen 37269, Germany
  • GSK Investigational Site
    Niedernhausen, Hessen 65527, Germany
  • GSK Investigational Site
    Wolfenbuettel, Niedersachsen 38302, Germany
  • GSK Investigational Site
    Hille, Nordrhein-Westfalen 32479, Germany
  • GSK Investigational Site
    Loehne, Nordrhein-Westfalen 32584, Germany
  • GSK Investigational Site
    Muenster, Nordrhein-Westfalen 48163, Germany
  • GSK Investigational Site
    Porta Westfalica, Nordrhein-Westfalen 32457, Germany
  • GSK Investigational Site
    Bad Kreuznach, Rheinland-Pfalz 55543, Germany
  • GSK Investigational Site
    Bodenheim, Rheinland-Pfalz 55294, Germany
  • GSK Investigational Site
    Frankenthal, Rheinland-Pfalz 67227, Germany
  • GSK Investigational Site
    Gerolstein, Rheinland-Pfalz 54568, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54290, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54294, Germany
  • GSK Investigational Site
    Worms, Rheinland-Pfalz 67547, Germany
  • GSK Investigational Site
    Doebeln, Sachsen 04720, Germany
  • GSK Investigational Site
    Singwitz, Sachsen 02692, Germany
  • GSK Investigational Site
    Lobenstein, Thueringen 07356, Germany
  • GSK Investigational Site
    Weimar, Thueringen 99425, Germany
  • GSK Investigational Site
    Berlin, 10315, Germany
  • GSK Investigational Site
    Berlin, 10967, Germany
  • GSK Investigational Site
    Berlin, 12627, Germany
  • GSK Investigational Site
    Berlin, 12679, Germany
  • GSK Investigational Site
    Berlin, 13355, Germany
  • GSK Investigational Site
    Berlin, 14197, Germany
  • GSK Investigational Site
    Bydgoszcz, 85-021, Poland
  • GSK Investigational Site
    Debica, 39-200, Poland
  • GSK Investigational Site
    Krakow, Poland
  • GSK Investigational Site
    Poznan, 61-709, Poland
  • GSK Investigational Site
    Siemianowice Slaskie, 41-103, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Wola, 43-225, Poland
  • GSK Investigational Site
    Bilbao, 48013, Spain
  • GSK Investigational Site
    Blanes (Girona), 17300, Spain
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28035, Spain
  • GSK Investigational Site
    Madrid, 28047, Spain
  • GSK Investigational Site
    Marid, 28040, Spain
  • GSK Investigational Site
    Montgat/Barcelona, 08390, Spain
  • GSK Investigational Site
    Málaga, 29011, Spain
  • GSK Investigational Site
    Móstoles/Madrid, 28935, Spain
  • GSK Investigational Site
    Sant Vicenç Dels Horts /Barcelona, 08620, Spain
  • GSK Investigational Site
    Tona/Barcelona, 08551, Spain
  • GSK Investigational Site
    Valladolid, 47010, Spain
  • GSK Investigational Site
    Vélez-Málaga / Málaga, 29700, Spain
09

References and documents

Publications

  • Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. PubMed 19325447 ↗
  • Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. PubMed 19325452 ↗
  • Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609. PubMed 19325450 ↗
  • Silfverdal SA, Coremans V, Francois N, Borys D, Cleerbout J. Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Expert Rev Vaccines. 2017 Feb;16(2):109-121. doi: 10.1586/14760584.2016.1164044. Epub 2016 Sep 30. PubMed 26954689 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in Jan 2008, 8 months.

Results were first posted in Aug 2009, 1 year 6 months after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2007
First posted
Apr 20, 2007
StartActual
Apr 25, 2007
Primary completionActual
Jan 21, 2008
CompletionActual
Jun 14, 2008
Results first posted
Aug 3, 2009
Last update
Jan 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00463437
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 20, 2007
Start date
Apr 25, 2007
Primary completion
Jan 21, 2008
Completion
Jun 14, 2008
Results posted
Aug 3, 2009
Last update
Jan 2, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PHiD-CV vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Pediarix

Start the discussion